A synthetic dye first used in the late 19th century may have changed how healthy brains handled attention and memory tasks within about 60 minutes of a single oral dose. That is the headline from a 2016 randomized brain-imaging trial in Radiology. It is a striking result, but the details matter more than the hype.
What the Researchers Actually Did
A team from the University of Texas Health Science Center at San Antonio and the University of Texas at Austin ran a prospective, randomized, double-blinded, placebo-controlled trial. They enrolled 26 healthy adults aged 22 to 62.
Each participant did functional MRI (fMRI) scans while completing two kinds of tasks:
- A psychomotor vigilance task, which measures sustained attention.
- Delayed match-to-sample tasks, which measure short-term memory.
Scans were taken before and one hour after participants received either low-dose oral methylene blue or a placebo. The team also ran a carbon dioxide challenge to measure cerebrovascular reactivity. Their statistical model was a 2 × 2 repeated-measures ANOVA (drug vs. placebo, before vs. after), with cluster-corrected P < .05 as the threshold for significance.
The Striking Findings
Attention: the insula lights up
During the sustained-attention task, methylene blue increased fMRI response in the bilateral insular cortex (Z = 2.9–3.4, P = .01–.008). The insula is involved in tracking internal states and in salience, the brain's "pay attention to this" system.
Memory: a wider network engaged
During the short-term memory task, methylene blue increased fMRI response across the prefrontal, parietal, and occipital cortex (Z = 2.9–4.2, P = .03–.0003). That spans regions tied to working memory, attention control, and visual processing.
The behavioral number: +7%
The imaging was paired with a performance result. Methylene blue was associated with a 7% increase in correct responses during memory retrieval (P = .01). Seven percent is modest, but it is a real behavioral signal alongside the imaging changes, from a single dose.
The authors concluded that low-dose methylene blue can increase fMRI activity during sustained attention and short-term memory tasks and enhance memory retrieval.
Why a Dye Would Do This
Methylene blue is an old compound with a long medical history, and it has been studied for its effects on mitochondrial function. Gonzalez-Lima, a co-author on this paper, has published extensively on the idea that it acts as an alternative electron carrier in mitochondria, which could support cellular energy metabolism in neurons. This trial's abstract reports brain activation and task performance, not mitochondrial measurements. So the mechanism is a plausible hypothesis here, not something this paper demonstrated.
The Fine Print: What This Study Can't Tell You
Before anyone gets carried away, consider the limits:
- Small sample. Twenty-six people, split between drug and placebo, is a modest trial.
- Single dose, single session. Effects were measured one hour after one dose. Nothing here speaks to repeated or long-term use.
- fMRI is an indirect readout. More activation is not automatically "better." The paper links the changes to task engagement and a 7% retrieval gain, but not to everyday cognition.
- Healthy adults only. The results don't tell us anything about people with cognitive impairment.
- Dose specifics. The abstract describes the dose only as "low-dose." Check the full text (PMC5084971) for the exact milligram amount rather than relying on secondhand numbers.
What This Means for You
Dose: The study doesn't give you a self-dosing protocol. Because the abstract specifies only "low-dose," and this was a controlled trial using a clinical-grade preparation, don't extrapolate from it to a supplement regimen. Read the full paper's methods and discuss any dose with a physician.
Timing: Brain effects were measured about one hour after a single oral dose. There is no data here on optimal timing, repeated dosing, or duration of benefit.
Who it might be relevant to: Mainly researchers and clinicians interested in cognition, and people curious about where the evidence stands. It is an early, mechanistic signal, not a treatment recommendation.
Who should skip it:
- Anyone taking SSRIs, SNRIs, or other serotonergic drugs (see below).
- Anyone with G6PD deficiency.
- Pregnant individuals.
- Anyone who wants a proven, long-term cognitive enhancer. This trial doesn't establish one.
Safety: Read This Section Twice
Methylene blue is not a harmless blue vitamin. It is a pharmacologically active compound.
- It is a serotonergic MAO inhibitor. Combined with SSRIs, SNRIs, and other serotonergic drugs, it can trigger serotonin syndrome, a potentially life-threatening condition. Symptoms include agitation, rapid heart rate, high temperature, tremor, and confusion.
- Avoid in G6PD deficiency. This inherited enzyme deficiency raises the risk of hemolytic anemia with methylene blue.
- Avoid in pregnancy.
- Pharmaceutical grade only. Industrial, aquarium, or lab-grade dyes can contain contaminants such as heavy metals and are not made for human consumption.
- Talk to a doctor first. Medication interactions are the most dangerous trap, and they are easy to miss without professional review.
The Bottom Line
This Radiology trial gives a small, well-controlled glimpse of what a century-old dye can do in the healthy human brain. Within an hour of one low oral dose, imaging showed more activity in attention and memory networks, and memory retrieval accuracy rose by 7%. The finding is intriguing, but it comes from one small, single-dose trial. Larger, longer studies are needed before anyone can say whether it translates into real-world benefit, and the interaction risks make DIY experimentation a poor idea.
